Treg cell treatment for graft-versus-host disease after stem cell transplant
Part of Immune system & allergy clinical trials.
This trial tests a new treatment using special white blood cells (called Treg cells) to help control graft-versus-host disease (GVHD), a common complication after a stem cell transplant. The goal is to reduce GVHD symptoms without the serious side effects of high-dose steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have had a stem cell transplant.
- You must have graft-versus-host disease (GVHD) that is still causing problems and needs treatment.
- You must have tried at least 1 but no more than 5 previous treatments for GVHD.
- Your steroid dose must be stable for 2 weeks before the trial, or if you are still on high-dose steroids without improvement, you may still qualify.
- You need to be in good overall health (able to care for yourself) and expected to live more than 12 months.
- You cannot be pregnant or breastfeeding, and if you could become pregnant, you must agree to use contraception during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests two different medicines (ATG-thymoglobulin and ATLG-grafalon) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for older adults with certain blood cancers who have a matched unrelated donor.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
This study tests a new cell therapy (CK0802) for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard steroid treatment. The treatment aims to control the immune response causing GVHD, potentially reducing symptoms and improving outcomes.
This trial tests whether giving special immune cells (regulatory T cells) grown in a lab, along with a low dose of interleukin-2, can help people with chronic graft-versus-host disease (GVHD) that hasn't improved with steroids. GVHD is a complication after a stem cell transplant where donor cells attack the patient's body.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
Hear when a new GVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.